Citations

Clear

1892 citation(s) found for "Wu, Kenneth".

020. IDENTIFICATION OF TARGET ANTIGENS FOR ANTI-ENDOTHELIAL CELL ANTIBODIES IN PATIENTS WITH TAKAYASU’S ARTERITIS USING PROTEOMICS
Karasawa, Rie , Sato, Toshiko , Tanaka, Megumi, Carette, Simon , Koening, Curry L. , Langford, Carol A. , McAlear, Carol A. , Sreih, Antoine G. , Ytterberg, Steven R. , Yudoh, Kazuo , Jarvis, James N. , Monach, Paul A. , Cuthbertson, David , Khalidi, Nader , Moreland, Larry W. , Pagnoux, Christian , Seo, Philip , Warrington, Kenneth J. , Merkel, Peter A.

Mayo Clinic

Rheumatology | March 29, 2019 | Volume: 58 | Issue: Supplement_2 | Pages: No page available

10.1093/rheumatology/kez057.019 Get It

269. GIANT CELL ARTERITIS WITH INTRACRANIAL VASCULITIS: A CASE SERIES
Hawkins, Alexander S., Crowson, Cynthia S. , Sánchez-Álvarez, Catalina , Koster, Matthew J. , Warrington, Kenneth J.

Mayo Clinic

Rheumatology | March 29, 2019 | Volume: 58 | Issue: Supplement_2 | Pages: No page available

10.1093/rheumatology/kez062.043 Get It

023. UTILITY OF SERUM FREE LIGHT CHAINS, ANTIPHOSPHOLIPID ANTIBODIES, AND CYTOKINES IN GIANT CELL ARTERITIS
Snyder, Melissa R. , Villatoro‐Villar, Michel , Crowson, Cynthia S. , Kermani, Tanaz A. , Koster, Matthew J. , Warrington, Kenneth J.

Mayo Clinic

Rheumatology | March 29, 2019 | Volume: 58 | Issue: Supplement_2 | Pages: No page available

10.1093/rheumatology/kez057.022 Get It

293. RITUXIMAB THERAPY FOR SYSTEMIC RHEUMATOID VASCULITIS: INDICATIONS, OUTCOMES, AND ADVERSE EFFECTS
Coffey, Caitrín M. , Richter, Michael , Crowson, Cynthia S. , Ytterberg, Steven R. , Makol, Ashima , Makol, Ashima , Koster, Matthew J. , Warrington, Kenneth J.

Mayo Clinic

Rheumatology | March 29, 2019 | Volume: 58 | Issue: Supplement_2 | Pages: No page available

10.1093/rheumatology/kez063.017 Get It

148. SHORT-FORM 36 AS A MEASURE OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH GIANT CELL ARTERITIS
Kermani, Tanaz A. , Sreih, Antoine G. , Tómasson, Gunnar , Carette, Simon , Forbess, Lindsy, Koening, Curry L. , McAlear, Carol A. , Ytterberg, Steven R. , Langford, Carol A. , Cuthbertson, David , Borchin, Renée , Khalidi, Nader , Monach, Paul A. , Moreland, Larry W. , Pagnoux, Christian , Seo, Philip , Spiera, Robert , Warrington, Kenneth J. , Merkel, Peter A.

Mayo Clinic

Rheumatology | March 29, 2019 | Volume: 58 | Issue: Supplement_2 | Pages: No page available

10.1093/rheumatology/kez059.025 Get It

Patients’ Medical and Psychosocial Experiences After Detection of a CDH1 Variant With Multigene Panel Testing
Hamilton, Jada G. , Brandt, Amanda , Brower, Jamie , Symecko, Heather , Christian, Stephanie N. , Harstad, Tricia, Offit, Kenneth , Long, Jessica M. , Salo‐Mullen, Erin E. , Couch, Fergus J. , Garber, Judy E. , Robson, Mark E. , Domchek, Susan M.

Mayo Clinic

JCO Precision Oncology | March 28, 2019 | Volume: No volume available | Issue: 3 | Pages: 1-14

10.1200/po.18.00300 | PMID 31511843 Get It

PURPOSE Germline CDH1 pathogenic variants (PV) are associated with hereditary diffuse gastric cancer and lobular breast cancer. Although prevalence of CDH1 PV is low in the general population, detection of these variants is increasing with the growing use of multigene panel testing. Little is known about the experiences of individuals tested for CDH1 variants in the multigene panel testing era. METHODS Participants recruited from the Prospective Registry of Multiplex Testing completed a cross-sectional self-report survey regarding CDH1 genetic testing experiences, medical management, and psychosocial adaptation. RESULTS Discordance existed in interpretations of CDH1 results; 13.3% of cases had disagreements in variant classifications among commercial laboratories, and 21.4% had disagreements between participant self-report and ClinVar classification. Survey data were available from 57 individuals reporting either PV (n = 16) or variants of uncertain significance (VUS; n = 41). Those with PV were more likely than those with VUS to report receiving a recommendation for prophylactic gastrectomy, although only 40.0% of those with PV received this recommendation. Participants with VUS were less satisfied with their health care providers’ knowledge and reported less CDH1 knowledge, distress, and worry about discrimination. Participants with PV perceived greater breast cancer risks, but similar gastric cancer risks, as those with VUS. CONCLUSION Few individuals with CDH1 PV report receiving recommendations for prophylactic gastrectomy, and no differences in perceived gastric cancer risk were observed based on participants’ CDH1 results, suggesting serious unmet informational needs.
Staging of T1 esophageal adenocarcinoma with volumetric laser endomicroscopy: a feasibility study
Kamboj, Amrit K. , Muppa, Prasuna, Sawas, Tarek , Lutzke, Lori S., Buras, Matthew , Golafshar, Michael A. , Katzka, David A. , Iyer, Prasad G. , Smyrk, Thomas C. , Wang, Kenneth T. , Kahn, Allon , Leggett, Cadman L. , Buras, Matthew R , Golafshar, Michael

Mayo Clinic

Endoscopy International Open | March 22, 2019 | Volume: 07 | Issue: 04 | Pages: E462-E470

10.1055/a-0838-5326 | PMID 30931378 Get It

Abstract Background and study aims Precise staging in T1 esophageal adenocarcinoma (EAC) is critical in determining candidacy for curative endoscopic resection. High-frequency endoscopic ultrasound (EUS) has demonstrated suboptimal accuracy in T1 EAC staging due to insufficient spatial resolution. Volumetric laser endomicroscopy (VLE) allows for high-resolution wide-field visualization of the esophageal microstructure. We aimed to investigate the role of VLE in staging T1 EAC. Patients and methods Patients undergoing endoscopic mucosal resection (EMR) were prospectively enrolled and only T1 EAC cases were included. EMR specimens were imaged using second-generation VLE immediately after resection. VLE images were analyzed for signal intensity by depth and signal attenuation (dB/mm) in both cross-sectional and en-face orientation. A decision tree model was constructed to combine measured VLE parameters and delineate diagnostic thresholds. Results Thirty EMR scans were obtained – 15 T1a specimens from 9 patients and 15 T1b specimens from 11 patients. T1b specimen VLE scans exhibited higher signal intensity (P < 0.0001) and higher signal attenuation compared to T1a specimens (P = 0.03). A combination of signal attenuation and signal intensity at 150 µm depth yielded optimal diagnostic thresholds and an area under the curve (AUC) of 0.77. VLE signal attenuation was significantly associated with grade of differentiation, irrespective of EAC stage. Conclusions VLE signal intensity and signal attenuation are quantitatively distinct in T1a and T1b EAC and associated with grade of differentiation. This is the first study examining the role of VLE for staging of T1 EAC and demonstrates promising diagnostic performance. With further in vivo validation, VLE may serve a role in staging superficial EAC.
Results of NRG oncology/RTOG 9813: A phase III randomized study of radiation therapy (RT) and temozolomide (TMZ) versus RT and nitrosourea (NU) therapy for anaplastic astrocytoma (AA).
Chang, Susan M. , Cairncross, J. Gregory , Bahary, Jean-Paul , Dolinskas, Carol A., Aldape, Kenneth , Schiff, David , Jaeckle, Kurt A. , Brown, Paul D. , Barger, Geoffrey, Werner‐Wasik, Maria, Brachman, David, Peñas-Prado, Marta , Robins, H. Ian, Bélanger, Karl, Schultz, Christopher J. , Zhang, Peixin, Gilbert, Mark R. , Chakravarti, Arnab , Shih, Helen A. , Mehta, Minesh P.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 2002-2002

10.1200/jco.2015.33.15_suppl.2002 Get It